<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743871</url>
  </required_header>
  <id_info>
    <org_study_id>C0341001</org_study_id>
    <nct_id>NCT02743871</nct_id>
  </id_info>
  <brief_title>Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE AND/OR MULTIPLE INTRAVENOUS AND/OR SUBCUTANEOUS DOSES OF PF-06817024 IN HEALTHY SUBJECTS WHO MAY BE MILDLY ATOPIC, SUBJECTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, AND SUBJECTS WITH MODERATE-SEVERE ATOPIC DERMATITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and
      pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic
      rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic
      Dermatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study for Part 1 is to evaluate the safety and tolerability of PF-06817024
      in healthy subjects.

      The purpose of the study for Part 2 is to evaluate the safety and tolerability of PF-06817024
      in patients with chronic rhinosinusitis with nasal polyps.

      The purpose of the study for Part 3 is to evaluate the safety and tolerability of PF-06817024
      in patients with moderate-to-severe Atopic Dermatitis
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 27, 2016</start_date>
  <completion_date type="Anticipated">February 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to discharge from study (minimally 211 days after last dose in Part 1) that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug PF-06817024 was assessed by the investigator (Yes/No).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmax(dn))</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile from Time Zero to Infinity (AUCinf)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Single Dose Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve Within Dosing Interval (AUCtau)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Concentration-Time Curve Within Dosing Interval (AUCtau (dn))</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration Over Dosing Interval (Cav)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Single Dose Cohorts, Last (Second) Dose of Multiple Dose Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>IV Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>IV Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>SC Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>SC Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulated Ratio for Maximum Observed Plasma Concentration (Rac(Cmax))</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Last (Second) Dose IV Cohorts, Last (Second) Dose SC Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulated Ratio for Area Under the Concentration-Time Curve Without Dosing Interval (Rac(AUCtau))</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Last (Second) Dose IV Cohorts, Last (Second) Dose SC Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-Drug Antibody (ADA)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>All cohorts; The percentage of participants with positive ADA and neutralizing antibodies will be summarized for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Baseline (Day 0) up to discharge from study (minimally 211 days after last dose in Part 1)</time_frame>
    <description>Single Dose Cohorts</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Healthy</condition>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg subcutaneous dose of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose to be determined of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06817024 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given one dose of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given one dose of placebo for PF-06817024 intravenously</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given one dose of PF-06817024 subcutaneously</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given one dose of placebo for PF-06817024 subcutaneously</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given two doses of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given two doses of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given 2 doses intravenously</description>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_label>Cohort 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given 2 doses intravenously</description>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_label>Cohort 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given doses of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given doses of Placebo intravenously</description>
    <arm_group_label>Cohort 13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55
             years of age (Part 1)

          -  Male subjects, female subjects of non-childbearing potential, female subjects of
             childbearing potential with documented bilateral tubal ligation (tubes tied) or
             bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following
             symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or
             reduction/loss of smell (Part 2)

          -  Male or female subjects between the ages of 18 and 75 years, inclusive with
             moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and
             not to use tanning booths, sun lamps, or other ultraviolet light sources during the
             study (Part 3)

        Exclusion Criteria:

          -  Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.),
             positive urine drug test, fever within 7 days of dosing, active infections within 28
             days of dosing (Part 1 and 2 and 3)

          -  History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part
             2)

          -  Exposure to live or attenuated vaccines, have skin conditions other than Atopic
             Dermatitis, use of JAK inhibitors and biologics (Part 3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis CTSC Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Physicians of Connecticut</name>
      <address>
        <city>Shelton</city>
        <state>Connecticut</state>
        <zip>06484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ear, Nose &amp; Throat Specialty Care of Minnesota, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research, LLC</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Phase 1 Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, PC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Medical Associates, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C0341001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FIH, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, Atopic Dermatitis, Chronic Rhinosinusitis, Nasal Polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

